Recent studies have pointed to the role of GPR39 expression in antidepressant treatment, but little is known about the interactions between specific receptors.
Columbia University has presented non-hallucinogenic ariadne analogues acting as 5-HT2A receptor agonists reported to be useful for the treatment of depression, among other disorders.
At first blush, to say that depression occurs with other diseases may seem like belaboring the obvious. After all, to put it in the bluntest possible terms, it’s sad to be sick. But by looking more closely, it soon becomes clear that the association is stronger than that. The strongest association between depression and other diseases, Stefan Gold told the audience at the European College of Neuropsychopharmacology (ECNP) annual conference in Vienna this week, is “not necessarily the most severe or most immediately life-threatening disorders… [it’s] across the spectrum."
“Epilepsy is really a classical neurological disorder,” Lars Pinborg told the audience at the European College of Neuropsychopharmacology (ECNP) annual conference on Sunday. “Or is it?” Pinborg, of Rigshospitalet's The Neuroscience Center in Denmark, was chairing a session dedicated to an alternative hypothesis, summed up in the session title: “Is epilepsy a psychiatric disorder?”
Marvel Biotechnology Inc. has synthesized purine compounds acting as adenosine A2A receptor (ADORA2A) antagonists reported to be useful for the treatment of cancer, depression, multiple sclerosis, nonalcoholic steatohepatitis (NASH), scleroderma, attention deficit hyperactivity disorder (ADHD), and Parkinson's and Alzheimer's diseases.
Gate Neurosciences Inc. was first founded in 2019, but officially launched last week with two clinical-stage assets and a bold goal: to develop better drugs for CNS disorders and identify better-suited patients for those drugs. The company’s first molecular target is the NMDA receptor. Gate has acquired the rights to two NMDA receptor modulators, zelquistinel and apimostinel.
Following the readout of a phase II trial evaluating its COVID-19 oral antiviral Pentarlandir (SNB-01), Taiwan’s Syneurx International Corp. said it expects to launch a phase III test of the candidate in the next few months.
Bipolar disorder (BPD) is disabling, destructive and notoriously difficult to diagnose. Research indicates that up to 40% of patients diagnosed with major depressive disorder or unipolar depression actually have BPD and treating them with antidepressants alone runs an elevated risk of worsening their condition. But the issue is not one-sided: other studies found that 30% to 60% of patients diagnosed with BPD do not meet the clinical criteria for the illness and may be taking powerful mood stabilizers needlessly while failing to receive potentially beneficial therapies.
By analyzing single-cell responses to ketamine administration, a multinational team of researchers has identified a potassium channel that contributes to the long duration of ketamine administration.
Wysa Ltd.’s artificial intelligence-based digital therapy received FDA breakthrough device designation for adults with chronic musculoskeletal pain, depression and anxiety. The device delivers cognitive behavioral therapy (CBT) via a digital companion or conversational agent on a smartphone.
